Repligen's Strong Q3 Recovery: CEO Says Pharma Orders Rebound, Analytics Business Grows
Portfolio Pulse from Vandana Singh
Repligen Corporation reported Q3 revenues of $141.19 million, down 30% Y/Y, but beating the consensus of $140.64 million. The company's Q3 adjusted EPS reached 23 cents, beating the consensus of 17 cents. Repligen completed the acquisition of Metenova for $164 million in cash and $9 million in equity consideration. The company forecasts FY23 adjusted EPS of $1.70-$1.76 and revenues of $635 million-$645 million. William Blair reiterated the Outperform rating for Repligen.
October 31, 2023 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Repligen reported better than expected Q3 results and completed an acquisition, which could strengthen its market position. The company's FY23 guidance and the Outperform rating from William Blair could positively impact the stock.
Repligen's Q3 results beat the consensus, indicating strong performance. The acquisition of Metenova could enhance its capabilities and market reach. The FY23 guidance shows the company's positive outlook. William Blair's Outperform rating indicates positive sentiment from analysts. All these factors could drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100